Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and GIP , appears to offer a significant development for obesity loss . Initial clinical tests have demonstrated impressive decreases in visceral tissue, conceivably exceeding existing obesity medications . However , further evaluation is needed to fully assess its sustained ef